Sonomind is a medical device company specializing in non-invasive brain stimulation utilizing low-intensity focused ultrasound to treat drug-resistant depression and other neurological and psychiatric conditions.
This portable device is the first to deliver precision transcranial ultrasound stimulation that is able to penetrate deep brain structures in an accurate, targeted and non-invasive manner. A custom-designed acoustic lens for each patient delivers low-intensity focused ultrasound, enabling ultrasound waves to pass through the skull and compensate for any distortion upon entering the brain.
Located in Paris, France, Sonomind has a staff of ten, headed by CEO Jeremy Bercoff. The company leverages 25 years of research undertaken by Profs. Mickael Tanter and Jean-François Aubry at the Institut Physique pour la Médecine (Inserm, ESPCI Paris - PSL, CNRS).
Sonomind has raised €2 million since inception
Company Details
- Employees
- 4
- Founded
- 2024
- Address
- Paris
- Industry
- Medical Equipment Manufacturing
- NAICS
-
Medical Equipment and Supplies ManufacturingSurgical and Medical Instrument ManufacturingSurgical Appliance and Supplies ManufacturingDental Equipment and Supplies ManufacturingOphthalmic Goods ManufacturingDental Laboratories
- Keywords
- des #patients.
Sonomind Questions
Sonomind's LinkedIn profile is https://www.linkedin.com/company/sonomind
Sonomind has
4 employees.
View email and phone details for 4
employees at Sonomind.
Sonomind's industry is
Medical Equipment Manufacturing
Sonomind's top competitors are
Bioserenity,
Microport Crm,
Physics For Medicine Paris,
Sonio,
Supersonic Imagine,
Echopole,
Brain Stimulation Journal,
Planmed,
Austral Dx,
Chipiron.
Sonomind's categories are Medical Equipment Manufacturing
Sonomind's founding year is 2024
